Acute myeloid leukemia is the most common type of leukemia in adults, yet it continues to
have the lowest survival rate of all leukemias. Prognosis for the elderly in particular …

Introduction: The standard anthracycline and cytarabine-based chemotherapy for acute
myeloid leukemia (AML) has changed relatively little since the 1970s and produces …

Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes.
Cytogenetic analysis reveals which patients may have favorable risk disease, but 5-year …

Abstract Purpose of Review The extensive genomic characterization of acute myeloid
leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We …

Standard treatment of acute myeloid leukemia (AML) results in a median survival of
approximately 1 year. Together with increasing understanding of the biology of AML, this …

The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the
past 3–4 decades with generally poor outcomes, especially in elderly populations unfit for …

Developments in investigational agents and novel regimens in acute myeloid leukemia
(AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting …

The treatment of acute myeloid leukemia (AML) in older patients is undergoing rapid
changes, with a number of important publications in the past five years. Because of this, a …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …

Simple Summary Acute Myeloid Leukemia is the most common aggressive blood cancer in
adults. Treatment for this condition is divided into induction followed by consolidation. The …